Orion Porfolio Solutions LLC Buys 1,796 Shares of Stryker Corporation $SYK

Orion Porfolio Solutions LLC raised its stake in shares of Stryker Corporation (NYSE:SYK) by 8.9% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 21,952 shares of the medical technology company’s stock after purchasing an additional 1,796 shares during the period. Orion Porfolio Solutions LLC’s holdings in Stryker were worth $8,115,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently made changes to their positions in the company. Clayton Financial Group LLC purchased a new stake in Stryker during the third quarter valued at $26,000. Elevation Point Wealth Partners LLC purchased a new position in shares of Stryker in the 2nd quarter worth $28,000. Kilter Group LLC bought a new stake in shares of Stryker in the 2nd quarter worth about $29,000. Howard Hughes Medical Institute bought a new stake in shares of Stryker in the 2nd quarter worth about $29,000. Finally, ANTIPODES PARTNERS Ltd purchased a new stake in shares of Stryker during the 3rd quarter valued at about $34,000. 77.09% of the stock is owned by institutional investors.

Stryker Stock Performance

Shares of NYSE:SYK opened at $364.11 on Friday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.21 and a current ratio of 1.89. The firm has a market cap of $139.34 billion, a PE ratio of 43.35, a price-to-earnings-growth ratio of 2.16 and a beta of 0.85. The firm’s 50 day simple moving average is $365.45 and its 200-day simple moving average is $369.14. Stryker Corporation has a one year low of $329.16 and a one year high of $404.87.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, January 29th. The medical technology company reported $4.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.40 by $0.07. Stryker had a return on equity of 24.41% and a net margin of 12.92%.The company had revenue of $7.17 billion for the quarter, compared to analysts’ expectations of $7.12 billion. During the same quarter in the prior year, the firm earned $4.01 earnings per share. Stryker’s revenue was up 11.4% compared to the same quarter last year. As a group, equities analysts predict that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be given a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, March 31st. This represents a $3.52 dividend on an annualized basis and a yield of 1.0%. Stryker’s dividend payout ratio (DPR) is presently 41.90%.

Insider Transactions at Stryker

In other Stryker news, Director Ronda E. Stryker sold 250,000 shares of the business’s stock in a transaction dated Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total value of $90,730,000.00. Following the completion of the transaction, the director directly owned 2,457,331 shares in the company, valued at approximately $891,814,566.52. The trade was a 9.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 5.90% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several research firms recently commented on SYK. Robert W. Baird set a $437.00 price target on Stryker in a research report on Friday, January 30th. Truist Financial lowered their price objective on Stryker from $400.00 to $392.00 and set a “hold” rating for the company in a research note on Thursday, December 18th. The Goldman Sachs Group set a $399.00 target price on Stryker in a report on Friday, January 9th. Needham & Company LLC boosted their target price on Stryker from $448.00 to $454.00 and gave the company a “buy” rating in a research report on Friday, January 30th. Finally, Royal Bank Of Canada restated an “outperform” rating and set a $435.00 price target on shares of Stryker in a report on Friday, November 14th. Fourteen research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $428.61.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.